ArticleInternational journal of general medicine2024
Sarcopenia as a Prognostic Factor and Multimodal Interventions in Breast Cancer.
Article in International journal of general medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of sarcopenia in esophageal cancer patients receiving preoperative neoadjuvant therapy: a systematic review and meta-analysis.International journal of clinical oncology · 2026Pooled it
- From malnutrition to multimodal care: a bibliometric and knowledge mapping analysis of frailty research in cancer.Frontiers in nutrition · 2026Pooled it
- Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Baseline Body Composition Characteristics and Overall Survival in Young Women with Breast Cancer: Matched Case-Control Study Nested Within a Cohort.Tomography (Ann Arbor, Mich.) · 2026Article
- Sarcopenia and inflammatory markers in early-stage breast cancer: a retrospective case-control study of NLR, MLR, RDW-CV, and HRR in middle-aged and elderly women.Frontiers in surgery · 2026Article
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
- Artificial intelligence standardizes CT-based body composition analysis in breast cacer to address methodological heterogeneity.Frontiers in oncology · 2026Review
- Revolutionizing osteoporosis management: the emerging role of immunotherapeutic and next-generation therapies.Inflammopharmacology · 2025Review
- Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to demonstrate the impact of sarcopenia on the prognosis of early breast cancer and its role in early multimodal intervention. Methods: The clinical data of patients (n=285) subjected to chemotherapy for early-stage breast cancer diagnosed pathologically between January 1, 2016, and December 31, 2020, in our hospital were retrospectively analyzed. Accordingly, the recruited subjects were divided into sarcopenia (n=85) and non-sarcopenia (n=200) groups according to CT diagnosis correlating with single-factor and multifactorial logistic regression analyses. Further, the breast cancer patients combined with sarcopenia were randomly divided into multimodal, nutritional, exercise, and control intervention groups. Multimodal interventions combined supervised exercise programs and tailored nutritional support. The preliminary data and post-operative efficacy, as well as post-operative survival of patients of the four groups, were compared. Results: Sarcopenia significantly reduced overall survival (OS) rates at 1 year (82.94% vs 85.78%), 3 years (81.76% vs 83.91%), and 5 years (80.59% vs 81.17%) compared to non-sarcopenia patients (P<0.001). Patients in the multimodal intervention group showed better outcomes, including improved ALB levels, reduced complication rates (4.5% vs 18.18% vs 18.18% vs.52.63%), and fewer chemotherapy side effects. The multifactorial stepwise logistic regression analysis indicated that advanced age (OR: 1.512, 95% CI: 1.178-1.962, P < 0.001) and multimodal intervention pathways (OR: 5.333, 95% CI: 2.651-10.473, P < 0.001) were significant risk factors affecting patients'prognosis. Conclusion: Sarcopenia might be an independent risk factor leading to the increase of post-operative complications and the shortening of long-term survival of patients. Moreover, the multimodal intervention of nutrition combined with exercise could effectively improve the quality of the prognosis of patients with important clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.